This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hicks, M. J. Articles by Wang, L. L. Search for Related Content PubMed Articles by Hicks, M. J. Articles by Wang, L. L. Social Bookmarking                            What's this?

Clinicopathologic Features of Osteosarcoma in Patients With Rothmund-Thomson Syndrome

M. John Hicks, Jill R. Roth, Claudia A. Kozinetz, Lisa L. Wang

From the Baylor College of Medicine, Houston, TX

Address reprint requests to Lisa L. Wang, MD, Texas Children's Cancer Center, Baylor College of Medicine, 6621 Fannin MC 3-3320, Houston, TX 77030; e-mail: llwang{at}bcm.tmc.edu

Purpose Patients with Rothmund-Thomson syndrome (RTS) and RECQL4 gene mutations have an increased risk of developing osteosarcoma (OS). Because RTS is considered a genomic instability syndrome, patients may experience increased toxicity with chemotherapy. The purpose of this study was to summarize the clinical features and response to therapy of OS in patients with RTS. The results of this analysis will help to define treatment guidelines for this complex and rare condition.

Patients and Methods An international cohort of patients with RTS and OS was enrolled in an institutional review board–approved study at Baylor College of Medicine (Houston, TX). Medical records were reviewed, and the following information was extracted: clinical features, treatment, pathologic findings, and clinical outcome.

Results The median age at diagnosis of OS for the 12 patients was 10 years. The most common primary tumor sites were the long bones (femur, tibia); the most frequent histologic subtype was conventional OS. Histologic response to chemotherapy and outcome were similar to other published large series of sporadic OS. Eight patients are alive and disease free; four died as a result of cancer. Five patients required chemotherapy dose modifications, most commonly due to mucositis from doxorubicin.

Conclusion Our results indicate that patients with RTS and OS are younger, but that their clinical behavior is similar to patients with sporadic OS. Our report suggests that these patients should initially be treated with conventional doses of chemotherapy as prescribed by current protocols; however, cautious and careful clinical observation is warranted to monitor for enhanced doxorubicin sensitivity in patients with RTS.

Supported by NIH-NICHD K08HD42136, the Doris Duke Charitable Foundation Clinical Scientist Development Award, NIH-RR000188-42 (BCM-General Clinical Research Center), and NIH-HD024064 (BCM-Mental Retardation Developmental Disabilities Research Center, Tissue Culture Core).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. R. Mehollin-Ray, C. A. Kozinetz, A. E. Schlesinger, R. P. Guillerman, and L. L. Wang Radiographic Abnormalities in Rothmund-Thomson Syndrome and Genotype-Phenotype Correlation with RECQL4 Mutation Status Am. J. Roentgenol., August 1, 2008; 191(2): W62 - W66. [Abstract] [Full Text] [PDF]